Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle | Eli Lilly Cuts Cas…

Explore the latest developments concerning Eli Lilly cuts.

Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset.
Powered and implemented by FactSet Digital Solutions. 
Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ – New Privacy Policy

Fox News senior medical analyst Dr. Marc Siegel joins ‘Varney & Co.’ to discuss the mounting cost of Obamacare subsidies and a new study suggesting weight loss drugs could dull alcohol’s effects.

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect.

Eli Lilly Cuts Cash Prices for Zepbound Vials on LillyDirect

Eli Lilly (LLY, Financials) lowered the cash prices of its Zepbound weight-loss drug vials on LillyDirect, reducing the monthly cost for patients paying out of pocket. Beginning Dec. 1, the starting dose is available for $299 per month, while the 5-milligram dose is priced at $399 and all higher doses at $449. The new range brings down earlier monthly prices of $349 to $499.

Is LLY fairly valued? Test your thesis with our free DCF calculator.

As obesity treatments become more popular, Lilly is expanding its GLP-1 therapy availability. It comes just after the firm and the federal government reached deals to cut government prices, increase Medicare coverage for some patients, and provide cheaper choices on the TrumpRx platform.

Eli Lilly's price cut, Thanksgiving box office, trouble for gravestone makers and more in Morning Squawk

This is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.

Here are five key things investors need to know to start the trading day:

Last week's recovery rally allowed the Dow Jones Industrial Average and S&P 500 to both finish their seventh straight winning month. But technology stocks weren't able to regain as much ground, as investors weighed concerns about overspending on artificial intelligence.

Eli Lilly is getting in on the price-cutting action this morning. The pharma company said it's lowering the cash cost of single-dose vials of weight-loss drug Zepbound on its direct-to-consumer platform.

For more detailed information, explore updates concerning Eli Lilly cuts.

For more news…